Somewhere between 20% and 50% of PNH patients treated with Soliris or other drugs in the C5 inhibitor class can't get symptoms under ... and idiopathic membranous nephropathy (IMN).

The median survival after diagnosis is 10 years, although some patients can survive for decades with only minor symptoms ... and Idiopathic membranous nephropathy (phase 2).

The following is a summary of “Steroid-resistant nephrotic syndrome due to renal-limited thrombotic microangiopathy and ...

Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving ...

Atherosclerosis cardiovascular disease (ASCVD)-related mortality is higher in patients with lupus nephritis (LN) compared ...

Obinutuzumab could reshape the treatment of lupus nephritis, a life-threatening complication of lupus that has long lacked ...

The New England Journal of Medicine has published a detailed analysis of Genentech’s positive results from the Phase III REGENCY study of Gazyva® (Obinutuzumab) for people with active lupus nephritis ...

The first step is scheduling a $15 online appointment with one of Roman’s licensed medical professionals to assess your symptoms and come up with a treatment plan. If a Roman product or the ...

Its etiology is common with that of clinical hypothyroidism; clinical symptoms most often include weight gain and fatigue. Subclinical forms of hypothyroidism are of increasing interest ...

The late diagnosis of chronic kidney disease (CKD) is a global problem that limits the opportunity to initiate disease-modifying therapies. Artificial intelligence approaches using imaging or ...

The treatment procedures are required in the case of the severity of the condition. The patient then needs to go for a kidney ...